| Ytd | -28.84% | |
| 1y | 30.23% |
| Open | 15.47 | Prev Close | 15.67 | Low | 14.32 | High | 15.50 | Mkt Cap | 219.44M |
| Vol | 169.46K | Avg Vol | 159.00K | EPS | -1.59 | P/E | N/A | Forward P/E | -14.83 |
| Beta | 3.32 | Short Ratio | 21.41 | Inst. Own | 8.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 17.44 | 200-d Avg | 20.93 | 1yr Est | 38.00 |
GLSI News
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy
FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met in May 2026 and recommended
STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-posi
All European and US Sites to Treat Patients with Commercially Manufactured GP2The Company previously
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.58) per share which missed the
from the ASCO Annual Meeting 2026.The abstract is shown below and the poster being presented today c
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinica
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Gree
STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the
BABA: 5% | Alibaba shares are trading higher on Bloomberg report of company moving toward IPO of its
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy
Greenwich LifeSciences shares are trading higher Monday after the company announced it extended its
Greenwich LifeSciences stock hits a new 52-week high! Discover how Greenwich LifeSciences is streaml
Greenwich LifeSciences stock rose after Phase 3 data showed GLSI-100 cut breast cancer recurrence ra
A preliminary analysis of recurrence rates by two methods to estimate the reduction in recurrence ra
In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are currently
Flamingo-01 Progress to DateThe Company has achieved a major milestone by screening over 1,000 patie